

Ileana L Piñón

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4782926/publications.pdf>

Version: 2024-02-01

129
papers

13,787
citations

71102

41
h-index

21540

114
g-index

131
all docs

131
docs citations

131
times ranked

12666
citing authors

#	ARTICLE	IF	CITATIONS
1	Do PRO Measures Function the Same Way for all Individuals With Heart Failure?. <i>Journal of Cardiac Failure</i> , 2023, 29, 210-216.	1.7	2
2	Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 275-300.	1.8	11
3	Policy and Payment Challenges in the Postpandemic Treatment of Heart Failure: Value-Based Care and Telehealth. <i>Journal of Cardiac Failure</i> , 2022, 28, 835-844.	1.7	1
4	Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial. <i>Circulation</i> , 2022, 145, 184-193.	1.6	106
5	Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology. <i>European Journal of Heart Failure</i> , 2022, 24, 143-168.	7.1	41
6	Cost-Effectiveness of Coronary Artery Bypass Surgery Versus Medicine in Ischemic Cardiomyopathy: The STICH Randomized Clinical Trial. <i>Circulation</i> , 2022, 145, 819-828.	1.6	7
7	Medical Therapy During Hospitalization for Heart Failure With Reduced Ejection Fraction: The VICTORIA Registry. <i>Journal of Cardiac Failure</i> , 2022, 28, 1063-1077.	1.7	23
8	Assessing race and ethnicity differences in outcomes based on GDMT and target NT-proBNP in patients with heart failure with reduced ejection fraction: An analysis of the GUIDE-IT study. <i>Progress in Cardiovascular Diseases</i> , 2022, , .	3.1	1
9	Time to Re-Examine Maternity Leave in Cardiology Training. <i>Journal of the American College of Cardiology</i> , 2022, 79, 2127-2128.	2.8	0
10	Frailty Status Modifies the Efficacy of Exercise Training Among Patients With Chronic Heart Failure and Reduced Ejection Fraction: An Analysis From the HF-ACTION Trial. <i>Circulation</i> , 2022, 146, 80-90.	1.6	32
11	Atrial Natriuretic Peptide and Treatment With Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2021, 9, 127-136.	4.1	47
12	Reverse Cardiac Remodeling Following Initiation of Sacubitril/Valsartan in Patients With Heart Failure With and Without Diabetes. <i>JACC: Heart Failure</i> , 2021, 9, 137-145.	4.1	27
13	Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial. <i>European Heart Journal</i> , 2021, 42, 1203-1212.	2.2	114
14	Greater Pain Severity Is Associated with Worse Outcomes in Patients with Heart Failure. <i>Journal of Cardiovascular Translational Research</i> , 2021, 14, 984-991.	2.4	2
15	Differences in NT-proBNP Response and Prognosis in Men and Women With Heart Failure With Reduced Ejection Fraction. <i>Journal of the American Heart Association</i> , 2021, 10, e019712.	3.7	6
16	Association Between Angiotensin Receptor–Nepriylsin Inhibition, Cardiovascular Biomarkers, and Cardiac Remodeling in Heart Failure With Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2021, 14, e008410.	3.9	27
17	Implantable Cardioverter-Defibrillator Eligibility After Initiation of Sacubitril/Valsartan in Chronic Heart Failure: Insights From PROVE-HF. <i>Circulation</i> , 2021, 144, 180-182.	1.6	28
18	Temporal Trends and Factors Associated With Cardiac Rehabilitation Participation Among Medicare Beneficiaries With Heart Failure. <i>JACC: Heart Failure</i> , 2021, 9, 471-481.	4.1	38

#	ARTICLE	IF	CITATIONS
19	SGLT2 inhibitors: the story continues to unfold. <i>European Heart Journal</i> , 2021, , .	2.2	3
20	Empagliflozin in Heart Failure with a Preserved Ejection Fraction. <i>New England Journal of Medicine</i> , 2021, 385, 1451-1461.	27.0	2,143
21	Participation in a Heart Failure Clinical Trial. <i>Circulation: Heart Failure</i> , 2021, 14, e008242.	3.9	12
22	The influence of comorbidities on achieving an N-terminal pro-B-type natriuretic peptide target: a secondary analysis of the GUIDE-IT trial. <i>ESC Heart Failure</i> , 2021, , .	3.1	3
23	Race and Ethnicity in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2021, 78, 2589-2598.	2.8	27
24	Managing the economic challenges in the treatment of heart failure. <i>BMC Cardiovascular Disorders</i> , 2021, 21, 612.	1.7	4
25	Racial and Ethnic Differences in Biomarkers, Health Status, and Cardiac Remodeling in Patients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/Valsartan. <i>Circulation: Heart Failure</i> , 2020, 13, e007829.	3.9	18
26	Effect of patiomer on serum potassium in hyperkalemic patients with heart failure: Pooled analysis of 3 randomized trials. <i>Progress in Cardiovascular Diseases</i> , 2020, 63, 656-661.	3.1	4
27	Sex-based differences in biomarkers, health status, and reverse cardiac remodelling in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan. <i>European Journal of Heart Failure</i> , 2020, 22, 2018-2025.	7.1	21
28	The New Kids on the Block: Don't Delay. <i>Journal of Cardiac Failure</i> , 2020, 26, 811-812.	1.7	0
29	One Small Step . . . <i>JACC: CardioOncology</i> , 2020, 2, 596-598.	4.0	0
30	Reverse Cardiac Remodeling and Outcome After Initiation of Sacubitril/Valsartan. <i>Circulation: Heart Failure</i> , 2020, 13, e006946.	3.9	28
31	Acute Kidney Injury: To Be or Not to Be: That Is the Question: It's the Company It Keeps. <i>American Journal of Nephrology</i> , 2020, 51, 169-171.	3.1	0
32	Assessment of Limitations to Optimization of Guideline-Directed Medical Therapy in Heart Failure From the GUIDE-IT Trial. <i>JAMA Cardiology</i> , 2020, 5, 757.	6.1	74
33	A "Silent" Passenger Speaks Loudly. <i>JACC: Heart Failure</i> , 2020, 8, 289-290.	4.1	0
34	How Long Will We Play the Ostrich Game?. <i>Circulation: Heart Failure</i> , 2020, 13, e007043.	3.9	0
35	Evaluation of the effects of sodium-glucose cotransporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial. <i>European Journal of Heart Failure</i> , 2019, 21, 1279-1287.	7.1	205
36	Association of Change in N-Terminal Pro-B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 1085.	7.4	403

#	ARTICLE	IF	CITATIONS
37	Natriuretic Peptide Response and Outcomes in Chronic Heart Failure With Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1205-1217.	2.8	54
38	CABG Improves Outcomes in Patients With Ischemic Cardiomyopathy. <i>JACC: Heart Failure</i> , 2019, 7, 878-887.	4.1	37
39	Burden of medical comorbidities and benefit from surgical revascularization in patients with ischaemic cardiomyopathy. <i>European Journal of Heart Failure</i> , 2019, 21, 373-381.	7.1	12
40	Sex Differences in Heart Failure—Female Representation in Heart Failure Studies. <i>Current Cardiovascular Risk Reports</i> , 2019, 13, 1.	2.0	1
41	Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2019, 95, 1304-1317.	5.2	232
42	Clinical factors related to morbidity and mortality in high-risk heart failure patients: the GUIDE predictive model and risk score. <i>European Journal of Heart Failure</i> , 2019, 21, 770-778.	7.1	36
43	Stress-Induced Cardiomyopathy. <i>Heart Failure Clinics</i> , 2019, 15, 41-53.	2.1	18
44	Heart Failure Postdischarge Clinic: A Pharmacist-led Approach to Reduce Readmissions. <i>Current Problems in Cardiology</i> , 2019, 44, 100407.	2.4	15
45	Prevalent digoxin use and subsequent risk of death or hospitalization in ambulatory heart failure patients with a reduced ejection fraction—Findings from the Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) randomized controlled trial. <i>American Heart Journal</i> , 2018, 199, 97-104.	2.7	9
46	Sex differences in heart failure. <i>Clinical Cardiology</i> , 2018, 41, 211-216.	1.8	98
47	Rationale and methods of the Prospective Study of Biomarkers, Symptom Improvement, and Ventricular Remodeling During Sacubitril/Valsartan Therapy for Heart Failure (PROVE-HF). <i>American Heart Journal</i> , 2018, 199, 130-136.	2.7	71
48	Sex Difference in Patients With Ischemic Heart Failure Undergoing Surgical Revascularization. <i>Circulation</i> , 2018, 137, 771-780.	1.6	34
49	Government continues to have an important role in promoting cardiovascular health. <i>American Heart Journal</i> , 2018, 198, 160-165.	2.7	6
50	Clinical impact of implantable cardioverter-defibrillator in primary prevention of total mortality in non-ischaeamic cardiomyopathy: results from a meta-analysis of prospective randomized clinical trials. <i>Europace</i> , 2018, 20, f211-f216.	1.7	11
51	If It Is Not Health Care Access or Insurance Coverage, Then Why Do Racial Disparities Persist?. <i>JACC: Heart Failure</i> , 2018, 6, 421-423.	4.1	1
52	Economic and Quality-of-Life Outcomes of Natriuretic Peptide-Guided Therapy for Heart Failure. <i>Journal of the American College of Cardiology</i> , 2018, 72, 2551-2562.	2.8	20
53	Improving Provider Adherence to Guideline Recommendations in Heart Failure. <i>Current Heart Failure Reports</i> , 2018, 15, 350-356.	3.3	3
54	Managing the Economic Challenges in the Treatment of Heart Failure. <i>Progress in Cardiovascular Diseases</i> , 2018, 61, 476-483.	3.1	4

#	ARTICLE	IF	CITATIONS
55	The American Heart Association Heart Failure Summit, Bethesda, April 12, 2017. Circulation: Heart Failure, 2018, 11, e004957.	3.9	8
56	Renal Function and Exercise Training in Ambulatory Heart Failure Patients With a Reduced Ejection Fraction. American Journal of Cardiology, 2018, 122, 999-1007.	1.6	5
57	Differences Between Patients Enrolled Early and Late During Clinical Trial Recruitment. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, e004643.	2.2	0
58	Atrial fibrillation inducibility during cavo-tricuspid isthmus dependent atrial flutter ablation for the prediction of clinical atrial fibrillation. International Journal of Cardiology, 2017, 240, 246-250.	1.7	7
59	Aerobic exercise training and general health status in ambulatory heart failure patients with a reduced ejection fraction—Findings from the Heart Failure and A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) trial. American Heart Journal, 2017, 186, 130-138.	2.7	27
60	Exercise Training in Patients With Chronic Heart Failure and Atrial Fibrillation. Journal of the American College of Cardiology, 2017, 69, 1683-1691.	2.8	45
61	Effect of Natriuretic Peptide—Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction. JAMA - Journal of the American Medical Association, 2017, 318, 713.	7.4	386
62	Heart Failure Transitions of Care: A Pharmacist-Led Post-Discharge Pilot Experience. Progress in Cardiovascular Diseases, 2017, 60, 249-258.	3.1	30
63	Implementation of a Patient Navigator Program to Reduce 30-day Heart Failure Readmission Rate. Progress in Cardiovascular Diseases, 2017, 60, 259-266.	3.1	47
64	Beta blocker dose and markers of sympathetic activation in heart failure patients: interrelationships and prognostic significance. ESC Heart Failure, 2017, 4, 499-506.	3.1	42
65	Persistence of 123I-mIBG Prognostic Capability in Relation to Medical Therapy in Heart Failure (from) Tj ETQq1 1 0.784314 rgBT /Over	1.6	0
66	Personalized medicine and Hispanic health: improving health outcomes and reducing health disparities—a National Heart, Lung, and Blood Institute workshop report. BMC Proceedings, 2017, 11, 11.	1.6	22
67	Heart Failure Management and Development of Heart Failure Programs. , 2017, , 783-803.		0
68	Statins and Exercise Training Response in Heart Failure Patients. JACC: Heart Failure, 2016, 4, 617-624.	4.1	9
69	Donor Troponin and Survival After Cardiac Transplantation. Circulation: Heart Failure, 2016, 9, .	3.9	33
70	Hyperkalemia in Heart Failure. Journal of the American College of Cardiology, 2016, 68, 1575-1589.	2.8	86
71	Relation of Angina Pectoris to Outcomes, Quality of Life, and Response to Exercise Training in Patients With Chronic Heart Failure (from HF-ACTION). American Journal of Cardiology, 2016, 118, 1211-1216.	1.6	11
72	Frailty Assessment in Advanced Heart Failure. Journal of Cardiac Failure, 2016, 22, 840-844.	1.7	51

#	ARTICLE	IF	CITATIONS
73	Variables Measured During Cardiopulmonary Exercise Testing as Predictors of Mortality in Chronic Systolic Heart Failure. <i>Journal of the American College of Cardiology</i> , 2016, 67, 780-789.	2.8	157
74	Utility of Patient-Reported Outcome Instruments in Heart Failure. <i>JACC: Heart Failure</i> , 2016, 4, 165-175.	4.1	120
75	Microvascular obstruction detected by cardiac MRI after AMI for the prediction of LV remodeling and MACE: A meta-analysis of prospective trials. <i>International Journal of Cardiology</i> , 2016, 202, 344-348.	1.7	16
76	Improving Quality of Cardiac Care: A Global Mandate. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2015, 68, 924-927.	0.6	2
77	Sex Differences in Device Therapy for Heart Failure: Utilization, Outcomes, and Adverse Events. <i>Journal of Women's Health</i> , 2015, 24, 261-271.	3.3	25
78	Psychosocial Factors, Exercise Adherence, and Outcomes in Heart Failure Patients. <i>Circulation: Heart Failure</i> , 2015, 8, 1044-1051.	3.9	52
79	Non-invasive assessment of low risk acute chest pain in the emergency department: A comparative meta-analysis of prospective studies. <i>International Journal of Cardiology</i> , 2015, 187, 565-580.	1.7	24
80	Evaluation of the Incremental Prognostic Utility of Increasingly Complex Testing in Chronic Heart Failure. <i>Circulation: Heart Failure</i> , 2015, 8, 709-716.	3.9	9
81	Authorship in a multicenter clinical trial: The Heart Failureâ€”A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) Authorship and Publication (HAP) Scoring System Results. <i>American Heart Journal</i> , 2015, 169, 457-463.e6.	2.7	13
82	The Potential Role of Natriuretic Peptideâ€”Guided Management for Patients Hospitalized for Heart Failure. <i>Journal of Cardiac Failure</i> , 2015, 21, 233-239.	1.7	16
83	Exercise Training and Pacing Status in Patients With Heart Failure: Results From HF-ACTION. <i>Journal of Cardiac Failure</i> , 2015, 21, 60-67.	1.7	32
84	Cardiac Resynchronization Therapy in Women. <i>JAMA Internal Medicine</i> , 2014, 174, 1340.	5.1	168
85	Relationship Between Galectin-3 Levels and Mineralocorticoid Receptor Antagonist Use in Heart Failure: Analysis From HF-ACTION. <i>Journal of Cardiac Failure</i> , 2014, 20, 38-44.	1.7	28
86	The effects of exercise on cardiovascular biomarkers in patients with chronic heart failure. <i>American Heart Journal</i> , 2014, 167, 193-202.e1.	2.7	50
87	Clinical Implications of Chronicâ€”Heartâ€”Failure Phenotypes Definedâ€”byâ€”Cluster Analysis. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1765-1774.	2.8	197
88	From Acute Decompensated to Chronic Heart Failure. <i>American Journal of Cardiology</i> , 2014, 114, 1923-1929.	1.6	12
89	Exercise Capacity and Mortality in Patients With Ischemic Left Ventricular Dysfunction Randomized to Coronary Artery Bypass Graft Surgery or Medical Therapy. <i>JACC: Heart Failure</i> , 2014, 2, 335-343.	4.1	43
90	Rationale and Design of theâ€”GUIDE-ITâ€”Study. <i>JACC: Heart Failure</i> , 2014, 2, 457-465.	4.1	106

#	ARTICLE	IF	CITATIONS
91	Sex-Specific Mortality Risk by QRS Morphology and Duration in Patients Receiving CRT. <i>Journal of the American College of Cardiology</i> , 2014, 64, 887-894.	2.8	85
92	Effects of Exercise Training on Outcomes in Women With Heart Failure. <i>JACC: Heart Failure</i> , 2014, 2, 180-186.	4.1	40
93	Coronary Computed Tomography Angiography for the Detection of Cardiac Allograft Vasculopathy. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1992-2004.	2.8	122
94	Current challenges for clinical trials of cardiovascular medical devices. <i>International Journal of Cardiology</i> , 2014, 175, 30-37.	1.7	37
95	Biomarkers of Myocardial Stress and Fibrosis as Predictors of Mode of Death in Patients With Chronic Heart Failure. <i>JACC: Heart Failure</i> , 2014, 2, 260-268.	4.1	104
96	Abstract P320: Discordance of Framingham Risk Score and Reynolds Risk Score to Global Vascular Risk Score: Results from the Hispanic Community Health Study/Study of Latinos. <i>Circulation</i> , 2014, 129, .	1.6	0
97	The STICH Trial (Surgical Treatment for Ischemic Heart Failure). <i>JACC: Heart Failure</i> , 2013, 1, 400-408.	4.1	82
98	Race, exercise training, and outcomes in chronic heart failure: Findings from Heart Failure - A Controlled Trial Investigating Outcomes in Exercise Training (HF-ACTION). <i>American Heart Journal</i> , 2013, 166, 488-495.e1.	2.7	29
99	Left Bundle Branch Block Predicts Better Survival in Women Than Men Receiving Cardiac Resynchronization Therapy. <i>JACC: Heart Failure</i> , 2013, 1, 237-244.	4.1	45
100	Forecasting the Impact of Heart Failure in the United States. <i>Circulation: Heart Failure</i> , 2013, 6, 606-619.	3.9	2,206
101	A Randomized Controlled Trial of High-Dose Vitamin D 3 in Patients With Heart Failure. <i>JACC: Heart Failure</i> , 2013, 1, 84-90.	4.1	77
102	Hospital Strategies Associated With 30-Day Readmission Rates for Patients With Heart Failure. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2013, 6, 444-450.	2.2	293
103	Care and Outcomes of Hispanic Patients Admitted With Heart Failure With Preserved or Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2012, 5, 167-175.	3.9	48
104	Trends In Heart Failure Hospitalizations. <i>Current Heart Failure Reports</i> , 2012, 9, 346-353.	3.3	26
105	Heart Failure in Women. <i>Clinical Cardiology</i> , 2012, 35, 172-177.	1.8	34
106	Quality Improvement in Heart Failure: A Randomized Educational Intervention to Change Provider Behavior. <i>Congestive Heart Failure</i> , 2012, 18, 245-253.	2.0	7
107	Behavioral Intervention, Nutrition, and Exercise Trials in Heart Failure. <i>Heart Failure Clinics</i> , 2011, 7, 467-479.	2.1	1
108	Cardiovascular Disease in Women. <i>Cardiology in Review</i> , 2011, 19, 71-75.	1.4	14

#	ARTICLE	IF	CITATIONS
109	Disparities in Women with Heart Failure. <i>Current Cardiovascular Risk Reports</i> , 2011, 5, 261-265.	2.0	2
110	Transitions of Care in Heart Failure: The Case for Comparative Effectiveness Research. <i>Current Heart Failure Reports</i> , 2011, 8, 81-83.	3.3	0
111	Diastolic Dysfunction and Heart Failure With Preserved Ejection Fraction in Women. <i>Archives of Internal Medicine</i> , 2011, 171, 1088-9.	3.8	0
112	Cardiac Rehabilitation in Heart Failure: A Brief Review and Recommendations. <i>Current Cardiology Reports</i> , 2010, 12, 223-229.	2.9	12
113	Effects of Exercise Training on Health Status in Patients With Chronic Heart Failure. <i>JAMA - Journal of the American Medical Association</i> , 2009, 301, 1451.	7.4	631
114	Efficacy and Safety of Exercise Training in Patients With Chronic Heart Failure. <i>JAMA - Journal of the American Medical Association</i> , 2009, 301, 1439.	7.4	1,694
115	Baseline differences in the HF-ACTION trial by sex. <i>American Heart Journal</i> , 2009, 158, S16-S23.	2.7	40
116	Heart Failure in Women. <i>Journal of the American College of Cardiology</i> , 2009, 54, 491-498.	2.8	172
117	Heart Failure and A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION): Design and rationale. <i>American Heart Journal</i> , 2007, 153, 201-211.	2.7	206
118	AACVPR/ACC/AHA 2007 Performance Measures on Cardiac Rehabilitation for Referral to and Delivery of Cardiac Rehabilitation/Secondary Prevention Services. <i>Journal of the American College of Cardiology</i> , 2007, 50, 1400-1433.	2.8	258
119	Sleep symptoms and clinical markers of illness in patients with heart failure. <i>Sleep and Breathing</i> , 2005, 9, 127-133.	1.7	35
120	ACC/AHA Clinical Performance Measures for Adults With Chronic Heart Failure. <i>Circulation</i> , 2005, 112, 1853-1887.	1.6	221
121	Exercise and Heart Failure. <i>Circulation</i> , 2003, 107, 1210-1225.	1.6	890
122	Heart Failure in Women. <i>Cardiology in Review</i> , 2003, 11, 337-344.	1.4	17
123	The AHF SCENE II Preceptorship Program: Rationale and Design of an Educational Program to Optimize Management of Advanced Heart Failure. <i>Congestive Heart Failure</i> , 2000, 6, 319-324.	2.0	1
124	Evaluating Quality of Care for Patients With Heart Failure. <i>Circulation</i> , 2000, 101, E122-40.	1.6	130
125	A controlled trial of cardiac rehabilitation in the home setting using electrocardiographic and voice transtelephonic monitoring. <i>American Heart Journal</i> , 2000, 139, 543-548.	2.7	136
126	Tolerability of extended duration intravenous milrinone in patients hospitalized for advanced heart failure and the usefulness of uptitration of oral angiotensin-converting enzyme inhibitors. <i>American Journal of Cardiology</i> , 1999, 84, 894-899.	1.6	23

#	ARTICLE	IF	CITATIONS
127	Exercise and Heart Failure. Chest, 1996, 110, 1317-1327.	0.8	25
128	Criteria for use of intravenous milrinone in adult inpatients. American Journal of Health-System Pharmacy, 1995, 52, 1918-1919.	1.0	0
129	Impedance Cardiography. , 0, , 77-87.		0